Single versus double HSCT
. | No. of patients . | Follow-up, mo . | EFS (y follow-up) . | . | . | OS (y follow-up) . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study . | . | . | Single . | Double . | P . | Single . | Double . | P . | ||||
| IFM 9435 | 399 | 70 | 10% (7) | 20% (7) | .03 | 20% (7) | 42% (7) | .01 | ||||
| HOVON MM37 | 255 | 40 | 15% (4) | 29% (4) | .03 | 50% (4) | 55% (4) | .31 | ||||
| Bologna 9636 | 220 | 38 | 25 mo | 34 mo | .05 | 56 mo | 60 mo | NS | ||||
| MAG 9533 | 193 | 40 | 31 mo | 33 mo | .55 | 49 mo | 73 mo | .14 | ||||
. | No. of patients . | Follow-up, mo . | EFS (y follow-up) . | . | . | OS (y follow-up) . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study . | . | . | Single . | Double . | P . | Single . | Double . | P . | ||||
| IFM 9435 | 399 | 70 | 10% (7) | 20% (7) | .03 | 20% (7) | 42% (7) | .01 | ||||
| HOVON MM37 | 255 | 40 | 15% (4) | 29% (4) | .03 | 50% (4) | 55% (4) | .31 | ||||
| Bologna 9636 | 220 | 38 | 25 mo | 34 mo | .05 | 56 mo | 60 mo | NS | ||||
| MAG 9533 | 193 | 40 | 31 mo | 33 mo | .55 | 49 mo | 73 mo | .14 | ||||
NS indicates not significant.